Phase III INVICTUS Trial Evaluates Ripretinib in Advanced GIST
Margaret von Mehren, MD, discusses the rationale for evaluating ripretinib in patients with heavily pretreated advanced GIST in the phase III INVICTUS trial, which was presented at the ESMO Congress 2019.
Margaret von Mehren, MD, from the Fox Chase Cancer Center, discusses the rationale for evaluating ripretinib (DCC-2618) in patients with heavily pretreated advanced gastrointestinal stromal tumors (GIST) inthe phase III INVICTUS trial, which was presented at the European Society for Medical Oncology (ESMO) Congress 2019.
The tumors in patients with GIST are driven by mutations primarily in 2 genes, which includeKITand PDGFRα. There are 3 drugs currently approved by the FDA for the treatment of these patients, including imatinib (Gleevec), sunitinib (Sutent), and regorafenib (Stivarga), von Mehren says. Following treatment with these therapies, many patients are clinically well and healthy enough to proceed with more therapy. However, there is a lack of therapies available following the 3 FDA-approved drugs.
